Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 47.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 254,125 shares of the company’s stock after acquiring an additional 82,068 shares during the quarter. Los Angeles Capital Management LLC owned about 0.83% of Medpace worth $77,897,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Miller Howard Investments Inc. NY increased its stake in Medpace by 1.3% in the fourth quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock valued at $943,000 after purchasing an additional 39 shares during the last quarter. Schulhoff & Co. Inc. grew its position in shares of Medpace by 2.0% in the 3rd quarter. Schulhoff & Co. Inc. now owns 2,250 shares of the company’s stock valued at $545,000 after buying an additional 45 shares during the last quarter. Campbell Newman Asset Management Inc. raised its stake in Medpace by 0.4% during the 4th quarter. Campbell Newman Asset Management Inc. now owns 11,095 shares of the company’s stock worth $3,401,000 after acquiring an additional 46 shares in the last quarter. Treasurer of the State of North Carolina lifted its position in Medpace by 0.5% in the third quarter. Treasurer of the State of North Carolina now owns 10,230 shares of the company’s stock valued at $2,477,000 after acquiring an additional 50 shares during the last quarter. Finally, Sectoral Asset Management Inc. boosted its stake in Medpace by 4.9% in the third quarter. Sectoral Asset Management Inc. now owns 1,181 shares of the company’s stock valued at $286,000 after acquiring an additional 55 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

Shares of MEDP stock traded down $0.89 during midday trading on Thursday, hitting $396.97. The company had a trading volume of 101,782 shares, compared to its average volume of 249,280. Medpace Holdings, Inc. has a 52-week low of $197.39 and a 52-week high of $421.00. The company’s 50 day simple moving average is $398.32 and its 200 day simple moving average is $328.94. The stock has a market cap of $12.30 billion, a price-to-earnings ratio of 40.79, a PEG ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. The firm had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. Medpace’s quarterly revenue was up 17.7% on a year-over-year basis. During the same period last year, the firm posted $2.27 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 11.23 EPS for the current year.

Insider Activity

In related news, major shareholder Medpace Investors, Llc sold 50,000 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the transaction, the insider now directly owns 5,539,947 shares of the company’s stock, valued at $2,170,274,237.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, major shareholder Medpace Investors, Llc sold 50,000 shares of Medpace stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the sale, the insider now directly owns 5,539,947 shares in the company, valued at $2,170,274,237.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the transaction, the vice president now directly owns 15,181 shares in the company, valued at approximately $6,117,943. The disclosure for this sale can be found here. Insiders have sold a total of 204,442 shares of company stock valued at $82,702,867 over the last quarter. Corporate insiders own 20.30% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and lifted their target price for the stock from $340.00 to $450.00 in a research report on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 price objective for the company. Robert W. Baird increased their price objective on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Guggenheim lifted their target price on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, StockNews.com upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Moderate Buy” and a consensus price target of $443.00.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.